Results 21 to 30 of about 234,888 (250)
Systemic Lupus Erythematosus with and without Anti-dsDNA Antibodies: Analysis from a Large Monocentric Cohort [PDF]
, 2015 Objectives. The anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70–98% of patients test positive. We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the ...
Alessandri, Cristiano +9 more
core +1 more source
Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature [PDF]
, 2019 Drug-induced subacute cutaneous lupus erythematosus (SCLE) is the most common subtype of drug-induced systemic lupus erythematosus and has been associated with more than 100 drugs.
Marsch, Amanda F, Shakhbazova, Anastasia
core
Belimumab : a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis [PDF]
, 2013 Objectives: To undertake a systematic review and meta-analysis to investigate clinical effectiveness of belimumab for patients with systemic lupus erythematosus (SLE) and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies.
Clarke, Aileen +9 more
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad +8 more
wiley +1 more source
, 2005 Toll-like receptor (TLR)-9 recognizes CpG motifs in microbial DNA. TLR9 signalling stimulates innate antimicrobial immunity and modulates adaptive immune responses including autoimmunity against chromatin, e.g., in systemic lupus erythematosus (SLE ...
Anders HJ, H-J Anders, Stacey KJ
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li +10 more
wiley +1 more source
The use of anti-ribosomal P antibodies in the diagnosis of cerebral lupus: superiority of western blotting over enzyme-linnked immunosorbent assay [PDF]
, 1998 This study investigated the use of anti-ribosomal P antibodies in the diagnosis of cerebral complications of systemic lupus erythematosus using two different methodsԸ?western blotting and enzyme-linked immunosorbent assay.
Chan, EYT +3 more
core
Systemic lupus erythematosus [PDF]
BMJ, 2007 Systemic lupus erythematosus in pregnancy brings risks for the mother, and possible harm to the fetus if the disease is treated.
Sarah J Germain +2 more
openaire +3 more sources
Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin +10 more
wiley +1 more source
Metabolic Consequences of Rheumatoid Arthritis
Arthritis Care &Research, EarlyView.Patients with rheumatoid arthritis (RA) may have metabolic disruption, which can contribute to adverse long‐term outcomes, for multiple reasons. Patients with RA appear to have a higher risk of sarcopenia, type 1 and type 2 diabetes mellitus, metabolic syndrome, and hypertension. Systemic inflammation in RA can cause a “lipid paradox,” with reduced low‐
Stevie Barry +2 more
wiley +1 more source